Table 2 Association between, on one hand, in vitro granulocyte responses, PBMC responses and baseline antibody levels and, on the other, baseline inflammatory markers, Larsen score and changes in Larsen score during the first 2 years after RA diagnosis
Baseline CRP | Baseline ESR | Baseline Larsen score | 1-year Larsen score | 2-year Larsen score | ∆ Larsen score 1 – 0 years | ∆ Larsen score 2 – 0 years | ∆ Larsen score 2 – 1 years | |
|---|---|---|---|---|---|---|---|---|
CD16 (PMN) | 35/16.5 (0.08) | 35.5/19.5 (0.26) | 14.4/5.5 (0.024) | 22.5/11.0 (0.034) | 24.0/31.1 (0.046) | 7.3/3.0 (0.08) | 9.0/6.3 (0.88) | 3.0/2.3 (0.27) |
CD66b (PMN) | 49/14 (0.004) | 33/19 (0.063) | 13.5/6.0 (0.15) | 22.0/11.0 (0.071) | 24.0/13.2 (0.059) | 7.5/2.6 (0.017) | 10.4/5.2 (0.016) | 5.1/2.3 (0.012) |
MPO (PMN) | 14/18 (0.6) | 19/21 (0.61) | 5.4/7.0 (0.69) | 17.0/11.0 (0.99) | 17.7/13.2 (0.97) | 6.9/2.8 (0.27) | 9.6/5.3 (0.41) | 2.5/2.3 (0.37) |
ΤΝFα (PBMC) | 28/17 (0.18) | 43/19 (0.049) | 9.3/6.3 (0.57) | 11.6/11.8 (0.75) | 15.3/13.2 (0.52) | 5.6/3.0 (0.50) | 9.4/5.3 (0.43) | 2.9/2.3 (0.48) |
Anti-CII | 36.5/14 (0.012) | 29/19 (0.10) | 11.5/6.3 (0.75) | 16.0/11.0 (0.44) | 15.0/13.5 (0.44) | 4.3/3.6 (0.21) | 8.1/5.3 (0.22) | 2.6/2.3 (0.29) |
Anti-CCP | 15/18.5 (0.20) | 23/20 (0.57) | 6.8/7.0 (0.76) | 13.0/10.5 (0.76) | 15.8/12.0 (0.42) | 4.6/2.5 (0.41) | 8.3/5.3 (0.12) | 3.0/1.5 (0.024) |
RF | 15/18 (0.65) | 23/20 (0.66) | 6.0/7.9 (0.17) | 11.0/12.0 (0.52) | 14.0/13.5 (0.64) | 4.4/3.6 (0.71) | 6.3/7.0 (0.44) | 3.0/1.8 (0.049) |